Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Nanoparticlized System: Promising Approach for the Management of Alzheimer’s Disease through Intranasal Delivery

Author(s): Shiv Bahadur*, Nidhi Sachan, Ranjit K. Harwansh and Rohitas Deshmukh

Volume 26, Issue 12, 2020

Page: [1331 - 1344] Pages: 14

DOI: 10.2174/1381612826666200311131658

Price: $65

Abstract

Alzheimer's disease (AD) is a neurodegenerative brain problem and responsible for causing dementia in aged people. AD has become most common neurological disease in the elderly population worldwide and its treatment remains still challengeable. Therefore, there is a need of an efficient drug delivery system which can deliver the drug to the target site. Nasal drug delivery has been used since prehistoric times for the treatment of neurological disorders like Alzheimer's disease (AD). For delivering drug to the brain, blood brain barrier (BBB) is a major rate limiting factor for the drugs. The desired drug concentration could not be achieved through the conventional drug delivery system. Thus, nanocarrier based drug delivery systems are promising for delivering drug to brain. Nasal route is a most convenient for targeting drug to the brain. Several factors and mechanisms need to be considered for an effective delivery of drug to the brain particularly AD. Various nanoparticlized systems such as nanoparticles, liposomes, exosomes, phytosomes, nanoemulsion, nanosphere, etc. have been recognized as an effective drug delivery system for the management of AD. These nanocarriers have been proven with improved permeability as well as bioavailability of the anti-Alzheimer’s drugs. Some novel drug delivery systems of anti-Alzheimer drugs are under investigation of different phase of clinical trials. Present article highlights on the nanotechnology based intranasal drug delivery system for the treatment of Alzheimer’s disease. Furthermore, consequences of AD, transportation mechanism, clinical updates and recent patents on nose to brain delivery for AD have been discussed.

Keywords: Intranasal route, novel drug delivery, nanotechnology, Alzheimer's disease, nanocarriers, intranasal.

« Previous Next »
[1]
Velayudhan L. Smell identification function and Alzheimer’s disease: a selective review. Curr Opin Psychiatry 2015; 28(2): 173-9.
[http://dx.doi.org/10.1097/YCO.0000000000000146] [PMID: 25594420]
[2]
de la Monte SM. Early intranasal insulin therapy halts progression of neurodegeneration: progress in Alzheimer’s disease therapeutics. Aging Health 2012; 8(1): 61-4.
[http://dx.doi.org/10.2217/ahe.11.89] [PMID: 26855666]
[3]
Patel A, Surti N, Mahajan A. Intranasal drug delivery: novel delivery route for effective management of neurological disorders. J Drug Deliv Sci Technol 2019; 52: 130-7.
[http://dx.doi.org/10.1016/j.jddst.2019.04.017]
[4]
Gurav AN. Alzheimer’s disease and periodontitis--an elusive link.Rev Assoc Med Bras (1992) 2014; 60(2): 173-80.
[http://dx.doi.org/10.1590/1806-9282.60.02.015 ] [PMID: 24919005]
[5]
Agrawal M, Saraf S, Saraf S, et al. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Control Release 2018; 281: 139-77.
[http://dx.doi.org/10.1016/j.jconrel.2018.05.011] [PMID: 29772289]
[6]
Misra A, Ganesh S, Shahiwala A, Shah SP. Drug delivery to the central nervous system: a review. J Pharm Pharm Sci 2003; 6(2): 252-73.
[PMID: 12935438]
[7]
Vasa DM, O’Donnell LA, Wildfong PL. Influence of dosage form, formulation, and delivery device on olfactory deposition and clearance: enhancement of nose-to-CNS uptake. J Pharm Innov 2015; 10: 200-10.
[http://dx.doi.org/10.1007/s12247-015-9222-9]
[8]
Wu H, Hu K, Jiang X. From nose to brain: understanding transport capacity and transport rate of drugs. Expert Opin Drug Deliv 2008; 5(10): 1159-68.
[http://dx.doi.org/10.1517/17425247.5.10.1159] [PMID: 18817519]
[9]
Khan AR, Yang X, Fu M, Zhai G. Recent progress of drug nanoformulations targeting to brain. J Control Release 2018; 291: 37-64.
[http://dx.doi.org/10.1016/j.jconrel.2018.10.004] [PMID: 30308256]
[10]
Kamei N, Tanaka M, Choi H, et al. Effect of an enhanced nose-to-brain delivery of insulin on mild and progressive memory loss in the senescence-accelerated mouse. Mol Pharm 2017; 14(3): 916-27.
[http://dx.doi.org/10.1021/acs.molpharmaceut.6b01134] [PMID: 28094952]
[11]
Quintana DS, Guastella AJ, Westlye LT, Andreassen OA. The promise and pitfalls of intranasally administering psychopharmacological agents for the treatment of psychiatric disorders. Mol Psychiatry 2016; 21(1): 29-38.
[http://dx.doi.org/10.1038/mp.2015.166] [PMID: 26552590]
[12]
Rassu G, Soddu E, Cossu M, et al. Solid microparticles based on chitosan or methyl-β-cyclodextrin: a first formulative approach to increase the nose-to-brain transport of deferoxamine mesylate. J Control Release : official journal of the Controlled Release Society 2015; 201:: 68-77.
[http://dx.doi.org/10.1016/j.jconrel.2015.01.025]
[13]
Shingaki T, Hidalgo IJ, Furubayashi T, et al. Nasal delivery of P-gp substrates to the brain through the nose-brain pathway. Drug Metab Pharmacokinet 2011; 26(3): 248-55.
[http://dx.doi.org/10.2133/dmpk.DMPK-10-RG-108] [PMID: 21317541]
[14]
Sachan N, Bahadur S, Sharma PK. Recent advances and novel approaches for nose to brain drug delivery for treatment of migraine. Drug Deliv Lett 2019; 9: 182-98.
[http://dx.doi.org/10.2174/2210303109666190508083142]
[15]
Martins PP, Smyth HDC, Cui Z. Strategies to facilitate or block nose-to-brain drug delivery. Int J Pharm 2019; 570: 118635-5.
[http://dx.doi.org/10.1016/j.ijpharm.2019.118635] [PMID: 31445062]
[16]
Bahadur S, Pathak K. Physicochemical and physiological considerations for efficient nose-to-brain targeting. Expert Opin Drug Deliv 2012; 9(1): 19-31.
[http://dx.doi.org/10.1517/17425247.2012.636801] [PMID: 22171740]
[17]
Raj R, Wairkar S, Sridhar V, Gaud R. Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity. Int J Biol Macromol 2018; 109: 27-35.
[http://dx.doi.org/10.1016/j.ijbiomac.2017.12.056] [PMID: 29247729]
[18]
Boche M, Pokharkar V. Quetiapine nanoemulsion for intranasal drug delivery: evaluation of brain-targeting efficiency. AAPS PharmSciTech 2017; 18(3): 686-96.
[http://dx.doi.org/10.1208/s12249-016-0552-9] [PMID: 27207184]
[19]
Choudhury H, Pandey M, Chin PX, et al. Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends. Drug Deliv Transl Res 2018; 8(5): 1545-63.
[http://dx.doi.org/10.1007/s13346-018-0552-2] [PMID: 29916012]
[20]
Giuliani A, Balducci AG, Zironi E, et al. In vivo nose-to-brain delivery of the hydrophilic antiviral ribavirin by microparticle agglomerates. Drug Deliv 2018; 25(1): 376-87.
[http://dx.doi.org/10.1080/10717544.2018.1428242] [PMID: 29382237]
[21]
Marianecci C, Rinaldi F, Hanieh PN, Paolino D, Marzio LD, Carafa M. Nose to brain delivery: new trends in amphiphile-based “soft” nanocarriers. Curr Pharm Des 2015; 21(36): 5225-32.
[http://dx.doi.org/10.2174/1381612821666150923095958] [PMID: 26412357]
[22]
Hanson LR, Frey WH II. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 2008; 9(Suppl. 3): S5.
[http://dx.doi.org/10.1186/1471-2202-9-S3-S5] [PMID: 19091002]
[23]
Lin T, Liu E, He H, et al. Nose-to-brain delivery of macromolecules mediated by cell-penetrating peptides. Acta Pharm Sin B 2016; 6(4): 352-8.
[http://dx.doi.org/10.1016/j.apsb.2016.04.001] [PMID: 27471676]
[24]
Goasdoué K, Miller SM, Colditz PB, Björkman ST. Review: The blood-brain barrier; protecting the developing fetal brain. Placenta 2017; 54: 111-6.
[http://dx.doi.org/10.1016/j.placenta.2016.12.005] [PMID: 27939102]
[25]
Timbie KF, Mead BP, Price RJ. Drug and gene delivery across the blood-brain barrier with focused ultrasound. J Control Release 2015; 219: 61-75.
[http://dx.doi.org/10.1016/j.jconrel.2015.08.059] [PMID: 26362698]
[26]
Tajes M, Ramos-Fernández E, Weng-Jiang X, et al. The blood-brain barrier: structure, function and therapeutic approaches to cross it. Mol Membr Biol 2014; 31(5): 152-67.
[http://dx.doi.org/10.3109/09687688.2014.937468] [PMID: 25046533]
[27]
Bitter C, Suter-Zimmermann K, Surber C. Nasal drug delivery in humansTopical Applications and the Mucosa. Karger Publishers 2011; pp. 20-35.
[http://dx.doi.org/10.1159/000321044]
[28]
Jiang Y, Zhu J, Xu G, Liu X. Intranasal delivery of stem cells to the brain. Expert Opin Drug Deliv 2011; 8(5): 623-32.
[http://dx.doi.org/10.1517/17425247.2011.566267] [PMID: 21417782]
[29]
Kulkarni AP, Govender DA, Kotwal GJ, Kellaway LA. Modulation of anxiety behavior by intranasally administered vaccinia virus complement control protein and curcumin in a mouse model of Alzheimer’s disease. Curr Alzheimer Res 2011; 8(1): 95-113.
[http://dx.doi.org/10.2174/156720511794604598] [PMID: 21143157]
[30]
Dhuria SV, Hanson LR, Frey WH II. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 2010; 99(4): 1654-73.
[http://dx.doi.org/10.1002/jps.21924] [PMID: 19877171]
[31]
Kushwaha SK, Keshari RK, Rai A. Advances in nasal trans-mucosal drug delivery. J Appl Pharm Sci 2011; 1: 21.
[32]
Chatterjee B. Nose to brain drug delivery: a recent update. J Formul Sci Bioavailab 2017; 1: 105.
[33]
Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis 2010; 37(1): 13-25.
[http://dx.doi.org/10.1016/j.nbd.2009.07.030] [PMID: 19664713]
[34]
Stockhorst U, Pietrowsky R. Olfactory perception, communication, and the nose-to-brain pathway. Physiol Behav 2004; 83(1): 3-11.
[http://dx.doi.org/10.1016/S0031-9384(04)00343-9] [PMID: 15501485]
[35]
Quintana DS, Smerud KT, Andreassen OA, Djupesland PG. Evidence for intranasal oxytocin delivery to the brain: recent advances and future perspectives. Ther Deliv 2018; 9(7): 515-25.
[http://dx.doi.org/10.4155/tde-2018-0002] [PMID: 29943688]
[36]
Majgainya S, Soni S, Bhat P. Novel approach for nose-to-brain drug delivery bypassing blood brain barrier by pressurized olfactory delivery device. J App Pharm 2015; 7: 148-63.
[http://dx.doi.org/10.21065/19204159.7.3.125]
[37]
Thorne RG, Pronk GJ, Padmanabhan V, Frey WH II. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004; 127(2): 481-96.
[http://dx.doi.org/10.1016/j.neuroscience.2004.05.029] [PMID: 15262337]
[38]
Jaiswal N, Sharma PK, Kumar A. Scope of nasal drug delivery: current challenges. World J Med Sci 2017; 14: 97-112.
[39]
Wen MM, El-Salamouni NS, El-Refaie WM, et al. Nanotechnology-based drug delivery systems for Alzheimer’s disease management: Technical, industrial, and clinical challenges. J Control Release 2017; 245: 95-107.
[http://dx.doi.org/10.1016/j.jconrel.2016.11.025] [PMID: 27889394]
[40]
Sood S, Jain K, Gowthamarajan K. Intranasal therapeutic strategies for management of Alzheimer’s disease. J Drug Target 2014; 22(4): 279-94.
[http://dx.doi.org/10.3109/1061186X.2013.876644] [PMID: 24404923]
[41]
Muntimadugu E, Dhommati R, Jain A, Challa VGS, Shaheen M, Khan W. Intranasal delivery of nanoparticle encapsulated tarenflurbil: A potential brain targeting strategy for Alzheimer’s disease. Eur J Pharm Sci 2016; 92: 224-34.
[http://dx.doi.org/10.1016/j.ejps.2016.05.012] [PMID: 27185298]
[42]
Elnaggar YS, Etman SM, Abdelmonsif DA, Abdallah OY. Intranasal piperine-loaded chitosan nanoparticles as brain-targeted therapy in Alzheimer’s disease: optimization, biological efficacy, and potential toxicity. J Pharm Sci 2015; 104: 3544-56.
[http://dx.doi.org/10.1002/jps.24557]
[43]
Ghasemi R, Haeri A, Dargahi L, Mohamed Z, Ahmadiani A. Insulin in the brain: sources, localization and functions. Mol Neurobiol 2013; 47(1): 145-71.
[http://dx.doi.org/10.1007/s12035-012-8339-9] [PMID: 22956272]
[44]
Corace G, Angeloni C, Malaguti M, et al. Multifunctional liposomes for nasal delivery of the anti-Alzheimer drug tacrine hydrochloride. J Liposome Res 2014; 24(4): 323-35.
[http://dx.doi.org/10.3109/08982104.2014.899369] [PMID: 24807822]
[45]
Vieira DB, Gamarra LF. Getting into the brain: liposome-based strategies for effective drug delivery across the blood-brain barrier. Int J Nanomedicine 2016; 11: 5381-414.
[http://dx.doi.org/10.2147/IJN.S117210] [PMID: 27799765]
[46]
Phachonpai W, Wattanathorn J, Muchimapura S, Tong-Un T, Preechagoon D. Neuroprotective effect of quercetin encapsulated liposomes: a novel therapeutic strategy against Alzheimer’s disease. Am J Appl Sci 2010; 7: 480-5.
[http://dx.doi.org/10.3844/ajassp.2010.480.485]
[47]
Arumugam K, Subramanian GS, Mallayasamy SR, Averineni RK, Reddy MS, Udupa N. A study of rivastigmine liposomes for delivery into the brain through intranasal route. Acta Pharm 2008; 58(3): 287-97.
[http://dx.doi.org/10.2478/v10007-008-0014-3] [PMID: 19103565]
[48]
Zheng X, Shao X, Zhang C, et al. Intranasal H102 peptide-loaded liposomes for brain delivery to treat Alzheimer’s disease. Pharm Res 2015; 32(12): 3837-49.
[http://dx.doi.org/10.1007/s11095-015-1744-9] [PMID: 26113236]
[49]
Al Asmari AK, Ullah Z, Tariq M, Fatani A. Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil. Drug Des Devel Ther 2016; 10: 205-15.
[PMID: 26834457]
[50]
Kela SK, Kaur CD. Pharmaceutical nanoemulsions an ardent carrier for drug delivery. Indo American J Pharm Res 2013; 3: 9202-12.
[51]
Bahadur S, Pathak K. Buffered nanoemulsion for nose to brain delivery of ziprasidone hydrochloride: preformulation and pharmacodynamic evaluation. Curr Drug Deliv 2012; 9(6): 596-607.
[http://dx.doi.org/10.2174/156720112803529792] [PMID: 22788695]
[52]
Fonseca-Santos B, Gremião MPD, Chorilli M. Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease. Int J Nanomedicine 2015; 10: 4981-5003.
[http://dx.doi.org/10.2147/IJN.S87148] [PMID: 26345528]
[53]
Ahmad E, Feng Y, Qi J, et al. Evidence of nose-to-brain delivery of nanoemulsions: cargoes but not vehicles. Nanoscale 2017; 9(3): 1174-83.
[http://dx.doi.org/10.1039/C6NR07581A] [PMID: 28009915]
[54]
Yadollahi R, Vasilev K, Simovic S. Nanosuspension technologies for delivery of poorly soluble drugs. J Nanomaterials 2015. 2015: 21635,13.
[http://dx.doi.org/10.1155/2015/216375]
[55]
Dodiya SS, Chavhan SS, Sawant KK, Korde AG. Solid lipid nanoparticles and nanosuspension formulation of Saquinavir: preparation, characterization, pharmacokinetics and biodistribution studies. J Microencapsul 2011; 28(6): 515-27.
[http://dx.doi.org/10.3109/02652048.2011.590612] [PMID: 21728760]
[56]
Somasundaram I, Sumathi S, Bhuvaneshwari S, Shafiq KM, Shanmugarajan T. Formulation and evaluation of hesperidin-loaded chitosan nanosuspension for brain targeting. Drug Invention Today 2018; p. 10.
[57]
Bhavna , Md S, Ali M, et al.Donepezil nanosuspension intended for nose to brain targeting: In vitro and in vivo safety evaluation. Int J Biol Macromol 2014; 67: 418-25.
[http://dx.doi.org/10.1016/j.ijbiomac.2014.03.022] [PMID: 24705169]
[58]
Morales-Prieto D, Stojiljkovic M, Diezel C, et al. Peripheral blood exosomes pass blood-brain-barrier and induce glial cell activation bioRxiv. 2018. Pre-print
[59]
Olsen ASB, Færgeman NJ. Sphingolipids: membrane microdomains in brain development, function and neurological diseases. Open Biol 2017; 7(5) 170069
[http://dx.doi.org/10.1098/rsob.170069] [PMID: 28566300]
[60]
Xiao T, Zhang W, Jiao B, Pan C-Z, Liu X, Shen L. The role of exosomes in the pathogenesis of Alzheimer’ disease. Transl Neurodegener 2017; 6: 3.
[http://dx.doi.org/10.1186/s40035-017-0072-x] [PMID: 28184302]
[61]
Zhuang X, Xiang X, Grizzle W, et al. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Ther 2011; 19(10): 1769-79.
[http://dx.doi.org/10.1038/mt.2011.164] [PMID: 21915101]
[62]
Yuyama K, Igarashi Y. Exosomes as carriers of Alzheimer’s amyloid-ß. Front Neurosci 2017; 11: 229-9.
[http://dx.doi.org/10.3389/fnins.2017.00229] [PMID: 28487629]
[63]
Long Q, Upadhya D, Hattiangady B, et al. Intranasal MSC-derived A1-exosomes ease inflammation, and prevent abnormal neurogenesis and memory dysfunction after status epilepticus. Proc Natl Acad Sci USA 2017; 114(17): E3536-45.
[http://dx.doi.org/10.1073/pnas.1703920114] [PMID: 28396435]
[64]
Choudhury H, Zakaria NFB, Tilang PAB, et al. Formulation development and evaluation of rotigotine mucoadhesive nanoemulsion for intranasal delivery. J Drug Deliv Sci Technol 2019; 54: 101301
[http://dx.doi.org/10.1016/j.jddst.2019.101301]
[65]
Ma T, Tan M-S, Yu J-T, Tan L. Resveratrol as a therapeutic agent for Alzheimer’s disease. BioMed Res Int 2014; 2014: 350516-6.
[http://dx.doi.org/10.1155/2014/350516] [PMID: 25525597]
[66]
Maiti P, Dunbar GL. Use of curcumin, a natural polyphenol for targeting molecular pathways in treating age-related neurodegenerative diseases. Int J Mol Sci 2018; 19(6): 1637.
[http://dx.doi.org/10.3390/ijms19061637] [PMID: 29857538]
[67]
Kocher A, Schiborr C, Behnam D, Frank J. The oral bioavailability of curcuminoids in healthy humans is markedly enhanced by micellar solubilisation but not further improved by simultaneous ingestion of sesamin, ferulic acid, naringenin and xanthohumol. J Funct Foods 2015; 14: 183-91.
[http://dx.doi.org/10.1016/j.jff.2015.01.045]
[68]
Langasco R, Fancello S, Rassu G, et al. Increasing protective activity of genistein by loading into transfersomes: A new potential adjuvant in the oxidative stress-related neurodegenerative diseases? Phytomed: Int J Phytother Phytopharm 2019; 52: 23-31.
[http://dx.doi.org/10.1016/j.phymed.2018.09.207]
[69]
Xu L, Zhang H, Wu Y. Dendrimer advances for the central nervous system delivery of therapeutics. ACS Chem Neurosci 2014; 5(1): 2-13.
[http://dx.doi.org/10.1021/cn400182z] [PMID: 24274162]
[70]
Katare YK, Daya RP, Sookram Gray C, et al. Brain targeting of a water insoluble antipsychotic drug haloperidol via the intranasal route using PAMAM dendrimer. Mol Pharm 2015; 12(9): 3380-8.
[http://dx.doi.org/10.1021/acs.molpharmaceut.5b00402] [PMID: 26226403]
[71]
Trompetero A, Gordillo A, Del Pilar MC, Cristina VM, Bustos Cruz RH. Alzheimer’s disease and Parkinson’s disease: a review of current treatment adopting a nanotechnology approach. Curr Pharm Des 2018; 24(1): 22-45.
[http://dx.doi.org/10.2174/1381612823666170828133059] [PMID: 28847307]
[72]
Kaur R. Intranasal drug delivery - New concept of therapeutic implications for effective treatment of CNS disorders. Int J Pharm Sci Res 2018; 8(6): 1000-7.
[73]
Li L, Feng Y, Hong Y, Lin X, Shen L. recent advances in drug delivery system for bioactive glycosides from traditional chinese medicine. Am J Chin Med 2018; 46(8): 1791-824.
[http://dx.doi.org/10.1142/S0192415X18500908] [PMID: 30482025]
[74]
Qian S, Wong YC, Zuo Z. Development, characterization and application of in situ gel systems for intranasal delivery of tacrine. Int J Pharm 2014; 468(1-2): 272-82.
[http://dx.doi.org/10.1016/j.ijpharm.2014.04.015] [PMID: 24709220]
[75]
NCT01767909. Therapeutic effects of intranasally administered insulin in adults having amnestic Mild Cognitive Impairment (aMCI) or Mild Alzheimer disease. Available at: https://clinicaltrials.gov/ct2/show/NCT01767909
[76]
NCT02503501A phase-II, single center, randomized, double-blind, placebo-controlled study of the safety and therapeutic effectiveness of intranasal glulisine in amnestic mild cognitive impairment and mild Alzheimer’s disease https://clinicaltrials.gov/ ct2/show/NCT02503501
[77]
NCT02569398. A Phase 2b/3 randomized, double-blind, placebocontrolled,parallel group, multicenter study investigating the efficacy and safety in subjects who are asymptomatic at risk for developing Alzheimer's dementia. https://clinicaltrials.gov/ ct2/show/NCT02569398
[78]
NCT02880956. Phase-2 multiple dose, multicenter, randomized,double-blind, placebo-controlled study to evaluate the efficacy and safety of abbv-8e12 in subjects with early alzheimer's disease https://clinicaltrials.ucsf.edu/trial/NCT02880956
[79]
NCT01056965. Randomized, double-blind, placebo-controlled pilot study of davunetide (nap, al-108) in predicted tauopathies. https://clinicaltrials.gov/ct2/show/NCT01056965
[80]
NCT01623310 Evaluating the safety of intranasal administration fluticasone bid using optinose device in subjects with cs with or without nasal polyps https://clinicaltrials.gov/ct2/ show/NCT01623310
[81]
NCT01504854. Phase II study to evaluate the impact on biomarkers of resveratrol treatment in patients with mild to moderate Alzheimer’s disease. https://clinicaltrials.gov/ct2/ show/NCT01504854
[82]
Thomas M DiMauro Mohamed Attawia Sean Lilienfeld Chantal HolyIntranasal red light probe for Alzheimer’s diseaseUnited States patent Available at: https://patents.google.com/patent/ US8734498B2/en
[83]
William H. Frey Leah Ranae Bresin.Use of Pet nanopeptide in treating and preventing neurodegenerative diseases. Available at: https://patents.google.com/ patent/ US9192654B2/en
[84]
William H, Frey, Hanson Sharon Pokropinski Francisco M, Rausa Iii. Treatment of central nervous sytem disorders by itranasal administration of immunoglobin G. European patent EP2961426A1 https://patents.google.com/patent/ EP2961426A1/no
[85]
William H. Frey, Samuel Scott Panter, Leah Ranae, Bresin Hanson, Annina Roeytenberg. Available at: https://patents.google.com/patent/US7776312B2/en
[86]
Alphareta AB. Available at: https://patents.google.com/patent/ US9402883B2/ en?oq=US14279589
[87]
Thomas M. Di Mauro Available at:. https://patents.google.com/patent/US20080076821A1/en?oq=US20080076821A1
[88]
Shon R. Pulley, James P. Beck, Ruth E. Ten, BrinkJon S. Jacobs. Available at: https://patents.google.com/ patent/US7067507B2/en?oq=US7067507B2
[89]
Rudolph E. Tanzi, Dora Kovacs, Aleister J. Saunders. Available at: https://patents.google.com/patent/US6472140B1/en?oq=US6472140B1
[90]
Kazuo Nagano, Kazuma Harada, Higashisaka Tsutsumi, Tomohiro Nakao. https://patents.google.com/patent/WO2018159852A1/en?oq=WO2018159852A1
[91]
Serguei DC, Rodolphe N. H Anthony brureau Available at:. https://patents.google.com/patent/WO2018197383A1/en?oq=WO2018197383A1
[92]
Kay Denis G. and Maclellan Alexander. Available at: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018148821
[93]
Atanasova M, Stavrakov G, Philipova I, Zheleva D, Yordanov N, Doytchinova I. Galantamine derivatives with indole moiety: Docking, design, synthesis and acetylcholinesterase inhibitory activity. Bioorg Med Chem 2015; 23(17): 5382-9.
[http://dx.doi.org/10.1016/j.bmc.2015.07.058] [PMID: 26260334]
[94]
Ravi PR, Aditya N, Patil S, Cherian L. Nasal in-situ gels for delivery of rasagiline mesylate: improvement in bioavailability and brain localization. Drug Deliv 2015; 22(7): 903-10.
[http://dx.doi.org/10.3109/10717544.2013.860501] [PMID: 24286183]
[95]
Hanafy AS, Farid RM, Helmy MW, ElGamal SS. Pharmacological, toxicological and neuronal localization assessment of galantamine/chitosan complex nanoparticles in rats: future potential contribution in Alzheimer’s disease management. Drug Deliv 2016; 23(8): 3111-22.
[http://dx.doi.org/10.3109/10717544.2016.1153748] [PMID: 26942549]
[96]
Zhou X, Li Y, Shi X, Ma C. An overview on therapeutics attenuating amyloid β level in Alzheimer’s disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels. Am J Transl Res 2016; 8(2): 246-69.
[PMID: 27158324]
[97]
Sunena, Singh SK, Mishra DN. Nose to brain delivery of galantamine loaded nanoparticles: in-vivo pharmacodynamic and biochemical study in mice. Curr Drug Deliv 2019; 16(1): 51-8.
[http://dx.doi.org/10.2174/1567201815666181004094707] [PMID: 30289074]
[98]
Calvo P, Remuñan-López C, Vila-Jato JL, Alonso MJ. Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res 1997; 14(10): 1431-6.
[http://dx.doi.org/10.1023/A:1012128907225] [PMID: 9358557]
[99]
Khunt D, Shrivas M, Polaka S, Gondaliya P, Misra M. Role of Omega-3 fatty acids and butter oil in targeting delivery of donepezil hydrochloride microemulsion to brain via the intranasal route: a comparative study. AAPS PharmSciTech 2020; 21(2): 45-5.
[http://dx.doi.org/10.1208/s12249-019-1585-7] [PMID: 31900652]
[100]
Torchilin VP. Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev 2008; 60(4-5): 548-58.
[http://dx.doi.org/10.1016/j.addr.2007.10.008] [PMID: 18053612]
[101]
Aktaş Y, Andrieux K, Alonso MJ, et al. Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor. Int J Pharm 2005; 298(2): 378-83.
[http://dx.doi.org/10.1016/j.ijpharm.2005.03.027] [PMID: 15893439]
[102]
Vergoni AV, Tosi G, Tacchi R, Vandelli MA, Bertolini A, Costantino L. Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. Nanomedicine (Lond) 2009; 5(4): 369-77.
[http://dx.doi.org/10.1016/j.nano.2009.02.005] [PMID: 19341816]
[103]
Shah B, Khunt D, Misra M, Padh H. Formulation and in-vivo pharmacokinetic consideration of intranasal microemulsion and mucoadhesive microemulsion of rivastigmine for brain targeting. Pharm Res 2018; 35(1): 8-8.
[http://dx.doi.org/10.1007/s11095-017-2279-z] [PMID: 29294189]
[104]
Available at: https://www.accessdata.fda.gov/scripts/cder/daf/ index.cfm
[105]
Watts P, Smith A. PecSys: in situ gelling system for optimised nasal drug delivery. Expert Opin Drug Deliv 2009; 6(5): 543-52.
[http://dx.doi.org/10.1517/17425240902939135] [PMID: 19413461]
[106]
Sharma A, Shaw SR. Efficacy of risperidone in managing maladaptive behaviors for children with autistic spectrum disorder: a metaanalysis.J Pediatric Health Care: official publication of National Association of Pediatric Nurse Associates & Practitioners 2012; 26:: 291-9.
[http://dx.doi.org/10.1016/j.pedhc.2011.02.008 ]
[107]
Kumar M, Misra A, Babbar AK, Mishra AK, Mishra P, Pathak K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm 2008; 358(1-2): 285-91.
[http://dx.doi.org/10.1016/j.ijpharm.2008.03.029] [PMID: 18455333]
[108]
Qureshi M, Aqil M, Imam SS, Ahad A, Sultana Y. Formulation and evaluation of neuroactive drug loaded chitosan nanoparticle for nose to brain delivery: in-vitro characterization and in-vivo behavior study. Curr Drug Deliv 2019; 16(2): 123-35.
[http://dx.doi.org/10.2174/1567201815666181011121750] [PMID: 30317997]
[109]
House E, Collingwood J, Khan A, Korchazkina O, Berthon G, Exley C. Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer’s disease. J Alzheimers Dis 2004; 6(3): 291-301.
[http://dx.doi.org/10.3233/JAD-2004-6310] [PMID: 15201484]
[110]
Esch FS, Keim PS, Beattie EC, et al. Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 1990; 248(4959): 1122-4.
[http://dx.doi.org/10.1126/science.2111583] [PMID: 2111583]
[111]
Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer’s disease: a randomised phase II trial. Lancet Neurol 2008; 7(6): 483-93.
[http://dx.doi.org/10.1016/S1474-4422(08)70090-5] [PMID: 18450517]
[112]
Imbimbo BP. Why did tarenflurbil fail in Alzheimer’s disease? J Alzheimers Dis 2009; 17(4): 757-60.
[http://dx.doi.org/10.3233/JAD-2009-1092] [PMID: 19542625]
[113]
Win KY, Feng S-S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005; 26(15): 2713-22.
[http://dx.doi.org/10.1016/j.biomaterials.2004.07.050] [PMID: 15585275]
[114]
Wang S, Chen P, Zhang L, Yang C, Zhai G. Formulation and evaluation of microemulsion-based in situ ion-sensitive gelling systems for intranasal administration of curcumin. J Drug Target 2012; 20(10): 831-40.
[http://dx.doi.org/10.3109/1061186X.2012.719230] [PMID: 22934854]
[115]
Vaz GR, Hädrich G, Bidone J, et al. Development of nasal lipid nanocarriers containing curcumin for brain targeting. J Alzheimers Dis 2017; 59(3): 961-74.
[http://dx.doi.org/10.3233/JAD-160355] [PMID: 28731428]
[116]
Li Y, Wang C, Zong S, et al. The trigeminal pathway dominates the nose-to-brain transportation of intact polymeric nanoparticles: evidence from aggregation-caused quenching probes. J Biomed Nanotechnol 2019; 15(4): 686-702.
[http://dx.doi.org/10.1166/jbn.2019.2724] [PMID: 30841963]

Rights & Permissions Print Cite
Article Metrics
53
11
© 2024 Bentham Science Publishers | Privacy Policy